Tedatioxetine (developmental code name Lu AA24530) is an experimental antidepressant that was discovered by scientists at Lundbeck; in 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine.[1]
 | |
 | |
| Clinical data | |
|---|---|
| Other names | Lu AA24530; Lu-AA-24530 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C18H21NS |
| Molar mass | 283.43 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Tedatioxetine is reported to act as a triple reuptake inhibitor (serotonin > norepinephrine > dopamine) and 5-HT2A, 5-HT2C, 5-HT3, and α1A-adrenergic receptor antagonist.[2][3][4][5]
As of 2009, it was in phase II clinical trials for major depressive disorder,[5] but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck's product pipeline.[6][7]
On May 10, 2016, all work on tedatioxetine stopped.[8]
A Chinese patent shows that there has been interest in this compound outside of Lundbeck.[9]
See also
editReferences
edit- ^ Beaulieu D (5 September 2007). "Lundbeck, Takeda enter strategic alliance for mood disorder, anxiety drugs]". First Word Pharma.
- ^ US 2010144788, Stensbol TB, Miller S, "4-[2-(4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression", published 10 June 2010, assigned to H Lundbeck AS
- ^ Stahl SM (19 May 2008). Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. p. 206. ISBN 978-0-521-88663-5. Retrieved 22 November 2011.
- ^ Stolerman IP (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105. ISBN 978-3-540-68698-9. Retrieved 22 November 2011.
- ^ a b "Lu AA24530 shows positive results in major depressive disorder phase II study". FierceBiotech. 2 July 2009.
- ^ "Pipeline of Lundbeck". Archived from the original on 28 September 2012. Retrieved 25 August 2013.
- ^ "Tedatioxetine". UK Medicines Information. Retrieved 20 January 2016.
- ^ "Tedatioxetine". AdisInsight. Springer Nature Switzerland AG. Retrieved 2016-06-09.
- ^ WO 2015090160, Cao, Longji; Xin, Jianchuang & Yang, Xiangping, "Compound for preparing 4-(2-(4-methylphenylthio))phenylpiperidine, and preparation method and use thereof", published 2015-06-25, assigned to NHWA Pharma Corp.
External links
edit
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |